Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT02926690

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02926690. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:03 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Study of OTS167PO, a MELK Inhibitor, to Evaluate Safety, Tolerability and Pharmacokinetics in Patients With Advanced Breast Cancer and Dose-Expansion Study in Patients With Triple Negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167 administered via oral capsule (PO) to patients with relapsed/refractory locally advanced or metastatic breast cancer.

Study identification

NCT ID: NCT02926690
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: OncoTherapy Science, Inc.; Industry
Enrollment: 70 participants

Conditions and interventions

Conditions

Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast Cancer

Interventions

OTS167PO Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: May 29, 2017 (Actual)
Primary completion: Sep 2027 (Estimated)
Completion: Sep 2027 (Estimated)
Last update posted: Feb 25, 2026

2017 – 2027

United States locations

U.S. sites: 8
U.S. states: 7
U.S. cities: 7

Facility	City	State	ZIP	Site status
Norwalk Hospital	Norwalk	Connecticut	06856	Completed
Emory University, Winship Cancer Institute	Atlanta	Georgia	30322	Recruiting
Kapi'olani Medical Center for Women & Children	Honolulu	Hawaii	96826	Recruiting
Dartmouth Cancer Center/Dartmouth-Hitchcock Medical Center	Lebanon	New Hampshire	03756	Recruiting
Weill Cornell Medicine \| NewYork-Presbyterian	New York	New York	10065	Completed
Memorial Sloan Kettering Cancer Center	New York	New York	11065	Completed
MD Anderson Cancer Center	Houston	Texas	77030	Completed
Froedtert Hospital & the Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02926690, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 25, 2026 · Synced Nov 12, 2026